The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Using FAERS Data and Clinical Evidence to Compare HER2+ Antagonists

Posted by Andrea Demakas on Feb 9, 2017 7:30:00 AM

Recently, Advera Health released a comparative safety report of the HER2+ Antagonists. In this drug review, we analyzed FDA Adverse Event Reporting System (FAERS) and clinical trial data to better understand how the drugs in this class stacked up.

Read More

Topics: FAERS, Clinical Trials, Clinical Evidence, Breast Cancer

Why Does Adverse Event Reporting to FAERS Continue to Accelerate?

Posted by Brian Overstreet on Oct 20, 2016 10:30:00 AM

Seventy two hours after 2016 Q2 FDA Adverse Event Reporting System (FAERS) data were publicly released by FDA, our RxFilter® process had it standardized and loaded into the Evidex platform.  Based on the volume of data in Q2, it looks like we’re well on the way to yet another record year of adverse events reported into FAERS. 

Here is a chart of new case reports (including our estimate for full year 2016).  Note that these numbers are based on a clean dataset; de-duplicated, primary suspect cases only).

Read More

Topics: FAERS

Honest Salespeople Aren’t Dead

Posted by Andrea Demakas on Jun 24, 2016 10:30:00 AM

I’m writing this in the lobby of a car dealership, waiting for my vehicle to get serviced. I brought a couple of sales books with me so I could utilize the 2 hour wait. I recently took on the added role of part-time sales rep within Advera Health as I have experienced successful case studies first-hand through being our client-facing Product Specialist over the past two years: I’ve built relationships with our existing clients, received their feedback on our data tools & analytics to see how they’ve implemented the information, and witnessed how our Evidex platform has become an integral part of their workflow.

Read More

Topics: FAERS, Payers, Formulary, Providers, Evidex

A Crystal Ball for FDA Action: How we Validated RxSignal

Posted by Dr. Keith Hoffman on Mar 11, 2016 10:30:00 AM

We are pleased to report that our latest major publication, “A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports” was released this week in the esteemed journal “Drug Safety.”  It was published as an online-first feature and will also appear in the April copy of the print version of Drug Safety.

Read More

Topics: FDA, FAERS, RxSignal

Watson Health is the Ultimate Data Parasite

Posted by Jim Davis on Mar 3, 2016 10:30:00 AM

One year after its birth, the ultimate data parasite has come of age by latching on to a $3 billion host. It is big, blue, pretty good at Jeopardy, and if you were to believe the data detractors, utterly useless.

Read More

Topics: Big Data, FAERS, Evidence

Data Is Everything… Or Is It? Why Data Management Matters

Posted by Brian Overstreet on Jan 7, 2016 10:43:05 AM

On Wednesday, Jan. 6, Forbes ran an article detailing a 7% drop in the price of Regeneron’s (REGN) stock price.  The company attributed that decline to investors obtaining data from the FDA Adverse Events Reporting System (FAERS) showing eight suicide cases from patient’s taking Regeneron’s new PCSK9 inhibitor Praluent (alirocumab).

The issue, of course, was that the people who obtained those data knew nothing about FAERS or its myriad problems with case duplications, incomplete records, or how to value reports submitted with multiple drugs and/or from dubious sources.

Read More

Topics: Big Data, FAERS, FOIA, Praluent, Regeneron, PCSK9

FDA is Slow so We FOIA

Posted by Brian Overstreet on Nov 13, 2015 10:39:06 AM

Since 1967, the Freedom of Information Act (FOIA) has provided the public the right to request access to records from any federal agency. It is often described as the law that keeps citizens in the know about their government. Federal agencies are required to disclose any information requested under the FOIA unless it falls under one of nine exemptions which protect interests such as personal privacy, national security, and law enforcement.

Read More


FAERS - Myths vs. Realities

Posted by Brian Overstreet on Oct 2, 2014 10:00:00 AM

The use of the FDA’s Adverse Event Reporting System (FAERS) for broad post-approval drug safety studies has long been curtailed due to three assumed limitations of the dataset. AdverseEvents has systematically set out to debunk all three of these myths through the use of peer-reviewed studies in major academic journals. This blog article summarizes our findings and we invite you to review our complete journal articles for more details.


Read More

Topics: FAERS, faers data

OpenFDA – the Good, the Bad, and the Ugly

Posted by Brian Overstreet on Jul 18, 2014 10:30:00 AM

On June 3rd, the FDA launched OpenFDA, in an attempt to take large internal datasets and make them more accessible and usable by the developer and business community.

OpenFDA is delivered in a search-based API that should enable software developers to more easily build applications based on adverse event data from the FDA Adverse Event Reporting System (FAERS) dataset for the period 1/1/2004 to 6/30/3013. The FDA has announced plans to add device and food adverse events data to the framework, along with structured product labeling and recall data (update: drug and device recall data was added on July 16). 

The launch was heralded with the sort of buzz and hoopla usually reserved for a major product launch from a Silicon Valley startup. I decided to hold off on any analysis and opinion until now to give our team the needed time to look through the system thoroughly.

Read More

Topics: Big Data, FAERS, OpenFDA

Broad Research Study Published in DRUG SAFETY Refutes the ‘Weber Effect'

Posted by Brian Overstreet on Mar 20, 2014 11:48:00 AM
I’m pleased to share our research paper that was published in the peer-reviewed journal Drug Safety this week that debunks one of the major limitations that has prevented the greater use of data from the FDA’s Adverse Event Reporting System (FAERS) for comparative drug studies and post-approval safety monitoring.

The full study can be downloaded here.
Read More

Topics: Drug Safety, FAERS, Weber Effect

Subscribe to Email Updates